AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MEDICAL
Fallout from Guidant stent ruling
The maker of cardiac-assist devices sank after its development of a drug-coated stent was blocked. Analysts said Guidant needed a favorable ruling to keep up with Boston Scientific and Johnson & Johnson. Guidant lost 5.10, or 16%, to 27.73. Angiotech Pharmaceuticals, which developed the paclitaxel-coated stent used in Guidant's tests, fell 4.62, or 12%.
** But rival Boston Scientific added 3.32, or 10%, to 35.60. J&J rose 2 to 58.30 and Surmodics, a J&J supplier, rose 2.12 to 34.35.
Immucor Q1 profit surged 109%
The maker of products used for blood transfusions earned 23 cents a share, beating views by 4 cents. Sales rose 25% to $23.2 mil. Results were boosted by new customer contracts and price hikes. Immucor expects to earn $1.10-$1.06 for the year on $95 mil-$96.5 mil in revenue. Analysts see 92 cents. Its shares rose 1.24, or 7%, to 18.36.
Health care cost set to rise 15%